Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Prospective Clinicogenomic Program
NCT04180176 · View on ClinicalTrials.gov ↗
Study Summary
The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.
Conditions Studied
Interventions
- OTHER Blood Draw
Study Locations (20)
Florida
- Florida Cancer Specialists; Department of Oncology — Fort Myers
- Florida Cancer Specialist, North Region — St. Petersburg
- SCRI Florida Cancer Specialists PAN — Tallahassee
- Florida Cancer Specialists — West Palm Beach
New York
- Hematology Oncology Associates of Central New York — East Syracuse
- West Clinic — New York
- National Translational Research Group — Port Jefferson Station
Alabama
- Alabama Oncology — Birmingham
- Clearview Cancer Institute — Huntsville
Georgia
- University Cancer & Blood Center, LLC; Research — Athens
- Piedmont Cancer Institute, PC — Atlanta
Arizona
- Ironwood Cancer & Research Centers — Chandler
Connecticut
- Yale University — New Haven
Indiana
- Fort Wayne Med Oncology & Hematology Inc — Fort Wayne
Michigan
- Cancer & Hematology Centers of Western Michigan — Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 945 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04180176
The ClinicalTrials.gov registry entry for NCT04180176 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 945 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 206 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Non-Small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention — of which Blood Draw is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04180176 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Florida, New York, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04180176 about?
NCT04180176 is a clinical study titled "Prospective Clinicogenomic Program". The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. ...
What is the current status of trial NCT04180176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 945 participants. The study started on 2019-12-13. Estimated completion is 2023-11-30.
What conditions does trial NCT04180176 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04180176?
The interventions under investigation include: Blood Draw (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04180176?
This trial is sponsored by Genentech, which has 206 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04180176 being conducted?
This trial has 20 study locations across Alabama, Arizona, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.